-
1
-
-
85025098013
-
-
World Health Organization Geneva
-
WHO. Global hepatitis report 2017, 2017, World Health Organization, Geneva.
-
(2017)
Global hepatitis report 2017
-
-
-
2
-
-
84962280759
-
Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens
-
Wilson, EM, Kattakuzhy, S, Sidharthan, S, et al. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis 62 (2016), 280–288.
-
(2016)
Clin Infect Dis
, vol.62
, pp. 280-288
-
-
Wilson, E.M.1
Kattakuzhy, S.2
Sidharthan, S.3
-
3
-
-
85013287732
-
Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection
-
Koizumi, Y, Ohashi, H, Nakajima, S, et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. Proc Natl Acad Sci USA 114 (2017), 1922–1927.
-
(2017)
Proc Natl Acad Sci USA
, vol.114
, pp. 1922-1927
-
-
Koizumi, Y.1
Ohashi, H.2
Nakajima, S.3
-
4
-
-
84995756438
-
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
-
Lau, G, Benhamou, Y, Chen, G, et al. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 1 (2016), 97–104.
-
(2016)
Lancet Gastroenterol Hepatol
, vol.1
, pp. 97-104
-
-
Lau, G.1
Benhamou, Y.2
Chen, G.3
-
5
-
-
85032275643
-
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in patients without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials
-
published online Aug 9.
-
Gane, EJ, Pianko, S, Roberts, SK, et al. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in patients without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30159-0.
-
(2017)
Lancet Gastroenterol Hepatol
-
-
Gane, E.J.1
Pianko, S.2
Roberts, S.K.3
-
6
-
-
85032295255
-
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in patients with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials
-
published online Aug 9.
-
Lawitz, E, Buti, M, Vierling, JM, et al. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in patients with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30163-2.
-
(2017)
Lancet Gastroenterol Hepatol
-
-
Lawitz, E.1
Buti, M.2
Vierling, J.M.3
-
7
-
-
84925607745
-
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
-
Kohli, A, Osinusi, A, Sims, Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 385 (2015), 1107–1113.
-
(2015)
Lancet
, vol.385
, pp. 1107-1113
-
-
Kohli, A.1
Osinusi, A.2
Sims, Z.3
-
8
-
-
85032264529
-
Shortening the duration of therapy for chronic hepatitis C infection
-
published online Aug 9.
-
Emmanuel, B, Wilson, EM, O'Brien, TR, Kottilil, S, Lau, G, Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol, 2017 published online Aug 9. http://dx.doi.org/10.1016/S2468-1253(17)30053-5.
-
(2017)
Lancet Gastroenterol Hepatol
-
-
Emmanuel, B.1
Wilson, E.M.2
O'Brien, T.R.3
Kottilil, S.4
Lau, G.5
-
9
-
-
84938751694
-
Modelling hepatitis C therapy-predicting effects of treatment
-
Perelson, AS, Guedj, J, Modelling hepatitis C therapy-predicting effects of treatment. Nat Rev Gastroenterol Hepatol 12 (2015), 437–445.
-
(2015)
Nat Rev Gastroenterol Hepatol
, vol.12
, pp. 437-445
-
-
Perelson, A.S.1
Guedj, J.2
|